|
|
 |
|
Viewing report
|
|
|
|
Big Pharma Mega-Mergers 1995-2014
Datamonitor, Dec 2009, Pages: 114
Mega-mergers (defined here as M&A events with deal sizes >$5bn) have been a long-term strategic feature of the pharmaceutical industry and have played a key role in shaping the structure and composition of today's leading companies. Is it possible to quantify exactly how much of Big Pharma's sales growth has been driven by M&A versus how much has been self-produced through organic growth?
Scope
- This report analyzes 22 large scale M&A events that have occurred to date within the Big Pharma peer set over the period 1995-2014
- Datamonitor has identified two distinct classes of M&A event: small/fast growth acquisitions and big/slow growth acquisitions.
- Using these two classes Datamonitor has identified three company-level M&A growth strategies that can be attributed to each of the Big Pharma players:
- In addition to the impact of mega-M&A on sales performance the report also assesses the financial implications associated with different M&A strategies
Highlights of this title
Twenty-two large-scale M&A events (defined as those valued above $5 billion) have occurred within Big Pharma over 19952014. Furthermore, every Big Pharma player has undertaken large scale M&A activity at some stage over this period, thereby illustrating it as an ingrained peer set strategy.
Over the period 19952014, Big Pharma prescription pharmaceutical sales are forecast to increase from $84 billion to $381 billion, with absolute growth of +$187 billion provided by M&A activity. In other words, two-thirds (c.63%) of Big Pharma sales expansion over a 20-year period will be driven entirely by M&A activity.
Key reasons to purchase this title
- Assess how much of Big Pharma's sales growth over 1995-2014 will be driven by M&A versus how much will be self-produced through organic growth.
- Assess how Datamonitor has classified each of the current Big Pharma players by their dominant M&A growth strategy
- Analyze the M&A and organic sales growth profiles for each Big Pharma company over the period 1995-2014
Customers who bought this item also bought
Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape
Big Pharma Performance Before, During and Beyond the Global Recession
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
EvaluatePharma® Yearbook - Company Performance Tables
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
What to Do When the R&D Pipeline Runs Dry
Pharmaceutical Licensing Overview
China Pharma Outsourcing Annual Review 2011
|
|
|
|
